Dr. Alan Olivero is a consultant specialising in Drug discovery and development. He is currently president of Olivero Consulting Inc. In 2018 he retired from Genentech, Inc., where he worked for 25 years, rising to the level of Senior Director of Discovery Chemistry and Head of Research Operations. In that role he oversaw much of the medicinal chemistry conducted at Genentech, leading research and Drug development teams.
Dr. Olivero’s research has contributed to programs in immunology, cardiovascular and neuro-degenerative disease, as well as his focus area of oncology.
Dr. Alan Olivero has a B.S degree in Chemistry from Stanford University, completed postgraduate work at the Swiss Federal Institute of Technology in Zurich (ETH), and received his Ph.D. in Organic Chemistry from Stanford University in 1988.
Dr. Olivero is passionate about finding new ways to tackle brain cancer. He was an invited speaker at the National Brain Tumour Society Scientific Summit in 2017 and was the co-organiser of the inaugural Drug Discovery Conference on CNS Malignancies in 2014. He has served on the Chemists in Cancer Research Steering Committee for the American Association of Cancer Research (AACR).
Dr. Olivero currently lives in the San Francisco Bay Area and consults for multiple biotechnology and pharma companies, including his former employer Genentech.
“I think a lot of neuro-oncologists are still looking at their patients and trying to give them hope… [However] there’s a lot of people out there who tell you all the ways you can fail, I’m not really impressed by them.”
